The latest review seeking to reassure clinicians about the safety of switching their patients to biosimilars focuses on rheumatology indications.
In recent months, a multiple papers have reported on the safety of switching patients from reference biologics to cost-saving biosimilars, including a systematic literature review that found that no new safety or efficacy concerns have been detected in more than 10 years and 700 million patient days of experience with biosimilar medicines.
The latest review seeking to reassure clinicians about the safety of switching their patients to biosimilars focuses on rheumatology indications. In the paper, Piotr Wiland, MD, PhD, and colleagues explain that, unlike the United States, which has a strict definition of biosimilar interchangeability that is part of federal law, in the European context, interchangeability refers to the possibility of exchanging 1 product for another that is expected to produce the same clinical effect. In Europe, interchangeability is not regulated by the European Medicines Agency, and EU member states make take their own positions on interchangeability.
In 2015, the review notes, the Dutch medical authority issued a statement saying that exchanging biologics is acceptable if adequate clinical monitoring is undertaken and if patients have been properly informed. Also in 2015, Finland issued its own statement saying that biosimilars are interchangeable with their reference products under the care of a provider.
The authors also underscore the fact that the biosimilarity concept is rooted in comparability, which has been used for decades to show the similarity of a drug before and after a manufacturing change; thus, biosimilarity is not a new concept, and from a regulatory and scientific perspective, biosimilars and reference products are different versions of the same active substance.
The authors acknowledge that among the key discussions on biosimilars is their immunogenicity, but highlight a 2017 study appearing in BioDrugs that found that all biologics used in treating inflammatory diseases, including biosimilar infliximab, have similar levels of immunogenicity (with the exception of etanercept, a fusion protein that has lower immunogenicity than products like adalimumab or rituximab). Furthermore, multiple factors impact immunogenicity of biologics, including active inflammatory disease or concomitant use of methotrexate.
The review also highlights reassuring findings for rheumatology indications from the EGALITY study, which assessed 3 treatment switches between biosimilar and reference etanercept; the NOR-SWITCH trial, which assessed the impact of switching between reference and biosimilar infliximab on patients with a range of immune-mediated inflammatory diseases; the PLANETRA and PLANETAS studies, which assessed switching from reference to biosimilar infliximab in patients with rheumatoid arthritis and ankylosing spondylitis, respectively; and the DANBIO registry, which has collected data on patients who switched from reference to biosimilar infliximab in Denmark. In each of these cases, switching was deemed safe and effective.
Because patients may be subject to the so-called “nocebo” effect when a switch is undertaken, the authors note, patients should be made aware of and should agree to a proposed switch, they and should be properly educated about the rigor of the biosimilar approval process in order to instill confidence in their treatment.
Finally, say the authors, while data on multiple switches between a reference and biosimilar are limited, the literature demonstrates that a single switch is not associated with any significant risk. Long-term observational studies and patient monitoring in registries will provide further data on multiple switches and will contribute to the growing body of knowledge on the feasibility of switching.
Reference
Wiland P, Batko B, Brzosko M, et al. Biosimilar switching—current state of knowledge. Rheumatologica. 2018;56(4):234-242. doi: 10.5114/reum.2018.77975.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.